<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907474</url>
  </required_header>
  <id_info>
    <org_study_id>EYN-MYD-TP-41</org_study_id>
    <nct_id>NCT04907474</nct_id>
  </id_info>
  <brief_title>Evaluation of Pupil Dilation Speed With the MAP Dispenser</brief_title>
  <acronym>SPEED</acronym>
  <official_title>A Study Evaluating Pupil Dilation Speed With the Micro-Array Print (MAP) Dispenser Comparing 2 Dosing Regimens of Tropicamide-Phenylephrine Fixed Combination Ophthalmic Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyenovia Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyenovia Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After screening, eligible subjects will be scheduled for 2 treatment visits where either 1&#xD;
      mist or 2 mists of the study drug will be administered to both eyes according to a&#xD;
      pre-specified randomization plan. Safety evaluations and efficacy measurements will be&#xD;
      performed at specified time intervals thereafter.&#xD;
&#xD;
      Pupil dilation for each treatment will be compared at each time interval.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Actual">June 3, 2021</completion_date>
  <primary_completion_date type="Actual">June 3, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in pupil diameter from baseline</measure>
    <time_frame>35 minutes post drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Mydriasis</condition>
  <arm_group>
    <arm_group_label>1 Mist</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One mist of tropicamide-phenylephrine fixed combination solution administered to each eye with the MAP Dispenser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Mists</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two mists of tropicamide-phenylephrine fixed combination solution administered to each eye with the MAP Dispenser</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tropicamide-phenylephrine fixed combination ophthalmic solution</intervention_name>
    <description>Tropicamide-phenylephrine fixed combination ophthalmic solution is a tropical drug solution for mydriasis</description>
    <arm_group_label>1 Mist</arm_group_label>
    <arm_group_label>2 Mists</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Photopic screening pupil diameter ≤ 3.5 mm in each eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to phenylephrine hydrochloride, tropicamide, or benzalkonium chloride.&#xD;
&#xD;
          2. Use of benzodiazepines, monoamine oxidase inhibitors, tricyclic antidepressants,&#xD;
             anticonvulsants, cholinergic drug at screening or anticipated during the study period.&#xD;
&#xD;
          3. History of closed-angle glaucoma.&#xD;
&#xD;
          4. Anatomically narrow anterior chamber angles (Van Herrick grade ≤ 2 in either eye).&#xD;
&#xD;
          5. Ocular surgery or laser treatment of any kind prior to the Screening Visit.&#xD;
&#xD;
          6. History of iris trauma, surgery, or atrophy.&#xD;
&#xD;
          7. Irregularly-shaped pupil secondary to ocular trauma or congenital defect, or history&#xD;
             of neurogenic pupil disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsontcho Ianchulev, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Eyenovia Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CODET Vision Institute</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mydriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tropicamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

